Effect of high-flux dialysis on circulating FGF-23 levels in end-stage renal disease patients: results from a randomized trial
Please always quote using this URN: urn:nbn:de:bvb:20-opus-148559
- Background
In patients undergoing maintenance hemodialysis (HD), increased levels of circulating fibroblast growth factor-23 (FGF-23) are independently associated with cardiovascular events and mortality. Interventional strategies aiming to reduce levels of FGF-23 in HD patients are of particular interest. The purpose of the current study was to compare the impact of high-flux versus low-flux HD on circulating FGF-23 levels.
Methods
We conducted a post-hoc analysis of the MINOXIS study, including 127 dialysis patients randomized toBackground
In patients undergoing maintenance hemodialysis (HD), increased levels of circulating fibroblast growth factor-23 (FGF-23) are independently associated with cardiovascular events and mortality. Interventional strategies aiming to reduce levels of FGF-23 in HD patients are of particular interest. The purpose of the current study was to compare the impact of high-flux versus low-flux HD on circulating FGF-23 levels.
Methods
We conducted a post-hoc analysis of the MINOXIS study, including 127 dialysis patients randomized to low-flux (n = 62) and high-flux (n = 65) HD for 52 weeks. Patients with valid measures for FGF-23 investigated baseline and after 52 weeks were included.
Results
Compared to baseline, a significant increase in FGF-23 levels after one year of low-flux HD was observed (Delta plasma FGF-23: +4026 RU/ml; p < 0.001). In contrast, FGF-23 levels remained stable in the high flux group (Delta plasma FGF-23: +373 RU/ml, p = 0.70). The adjusted difference of the absolute change in FGF-23 levels between the two treatment groups was statistically significant (p < 0.01).
Conclusions
Over a period of 12 months, high-flux HD was associated with stable FGF-23 levels, whereas the low-flux HD group showed an increase of FGF-23. However, the implications of the different FGF 23 time-trends in patients on high flux dialysis, as compared to the control group, remain to be explored in specifically designed clinical trials.…
| Author: | Andreas Schneider, Markus P. Schneider, Detlef H. Krieter, Bernd Genser, Hubert Scharnagl, Tatjana Stojakovic, Christoph Wanner, Christiane Drechsler |
|---|---|
| URN: | urn:nbn:de:bvb:20-opus-148559 |
| Document Type: | Journal article |
| Faculties: | Medizinische Fakultät / Medizinische Klinik und Poliklinik I |
| Language: | English |
| Parent Title (English): | PLoS ONE |
| Year of Completion: | 2015 |
| Volume: | 10 |
| Issue: | 5 |
| Pagenumber: | e0128079 |
| Source: | PLoS ONE 10(5): e0128079 (2015). DOI: 10.1371/journal.pone.0128079 |
| DOI: | https://doi.org/10.1371/journal.pone.0128079 |
| Dewey Decimal Classification: | 6 Technik, Medizin, angewandte Wissenschaften / 61 Medizin und Gesundheit / 610 Medizin und Gesundheit |
| Tag: | cardiovascular events; chronic kidney disease; fibroblast growth factor-23; hemodialysis; left ventricular hypertrophy; mineral metabolism; mortality; parathyroid hormone; phosphate homeostasis |
| Release Date: | 2018/11/15 |
| Licence (German): |  CC BY: Creative-Commons-Lizenz: Namensnennung 4.0 International |